Enveric Biosciences Initiates Genotoxicity Studies for Mental Health Drug Candidate EB-003

Enveric Biosciences has begun a series of genotoxicity studies for its lead drug candidate, EB-003, marking a formal step toward filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration. The company designed these preclinical trials to evaluate the safety profile of the compound, which is currently being developed as a potential treatment for mental health disorders.

These studies assess the potential for the drug candidate to cause genetic damage, a standard requirement for regulatory approval before human clinical trials can proceed. The data gathered from this testing phase will form a core component of the company’s future IND submission. EB-003 belongs to a class of compounds the company refers to as “neuroplastogens,” which are intended to promote neuroplasticity without inducing the hallucinogenic effects typically associated with traditional psychedelic therapies. Enveric Biosciences expects these results to provide the necessary safety documentation to support the advancement of the drug candidate into the next stage of its regulatory development.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI